Scientists are racing to stamp out the disease in Southeast Asia before unstoppable strains spread. This article features MORU, SMRU and colleagues, and explains what is happening and what we are doing to eliminate drug-resistant malaria in Southeast Asia before it spreads
ASTMH nominated Professor Rose McGready, SMRU Deputy Director, as an Honorary International Fellow. Rose received the prestigious award in recognition of outstanding accomplishment by an \u201cindividual not an American citizen who has made eminent contributions to some phase of tropical medicine and hygiene\u201d. Rose will formally receive her award at the ASTMH Annual Meeting, to be help 28 Oct-1 Nov in New Orleans, Louisiana.
The proliferation of poor quality medical products is an important but neglected public health problem, threatening millions of people all over the world, both in developing and wealthy countries. A pioneering conference will bring leading professionals from all over the world to Oxford, September 23-28, to discuss strategies for tackling poor quality medical products on a global scale.
Current recommended treatment regimens for the most widely used medicine for uncomplicated Plasmodium falciparum malaria may be sub-optimal for small children and pregnant women according to a study led by Professor Joel Tarning.
One of the world\u2019s most widely used anti-malarial drugs is safe to use, say researchers, after a thorough review and analysis of nearly 200,000 malaria patients who\u2019d taken the drug dihydroartemisinin-piperaquine (DHA-PPQ). There is such a low risk of sudden unexpected death from DHA-PPQ, one of the world\u2019s most effective medicines to treat malaria, that there is no need to limit its current use.
In this Science Blog published on Oxford University website, Prof Paul Newton, Head of the Medicine Quality Group at the Infectious Diseases Data Observatory (IDDO) and the MORU Tropical Health Network and NDM Professor of Tropical Medicine i, explains the need for new strategies for tackling poor quality medical products.
Primaquine can be used to prevent the transmission of falciparum malaria from human to mosquito. Bob Taylor and colleagues at the Mahidol Oxford Research Unit (MORU) have developed an age-based regimen for single low-dose primaquine to block the transmission of malaria in sub-Saharan Africa.
The first-ever dedicated academic conference to discuss Medicine Quality & Public Health bringing together people from a diversity of sectors: public health, national regulatory authority, pharmacy, biomedical, chemistry, law, ethics, cultural and social sciences, the pharmaceutical industry, international organisations, NGOs, national procurement centres, also scientists working on internet and pharmaceutical forensics. 23rd-28th September 2018 at Keble College, Oxford. Submit your abstract by 1 June 2018
On 10 May 2018, SMRU Deputy Director Rose McGready was awarded the Alumni Award for Service to Humanity by the University of Sydney. The Alumni Award recognizes the personal contribution of alumni who, through service to philanthropy, improve the lives of those in need. It also seeks to recognize the significant involvement of Sydney alumni in projects that enrich local or international communities.
The rapid elimination of potentially untreatable P. falciparum malaria in South-East Asia is possible, according to a ground-breaking new study published today in The Lancet. The study authors say that setting up community-based malaria clinics for early diagnosis, treatment and monitoring, combined with mass antimalarial drug administration (MDA) to everyone living in \u2018hotspot\u2019 areas.
ITV News has travelled across the world to report on the growing global threat of the spread of deadly drug-resistant 'super bugs'. In the first of their three-part series, they investigate the frontline fight against deadly malaria parasites in South East Asia threatening a new global emergency.
18 April 2018 (London) \u2013 The United Kingdom\u2019s Department for International Development (DFID) announced that it will commit \u00a39.2 million (USD 13.15 million) of research funding to DeTACT (Development of Triple Artemisinin Combination Therapies), a large multi-centre trial in 5 Asian and 10 African countries that aims to develop two new safe and effective malaria treatments using combinations of existing antimalarial drugs.
As the second largest international donor, the UK has been at the forefront of efforts to reduce the number of cases for many years by investing in treatment, prevention and research, including the fight against the threat of drug resistance. The UK has announced further support for the fight against malaria to save more than 120,000 lives ahead of a Malaria Summit tomorrow with Commonwealth leaders.
Pailin, a small settlement nestling in tropical rainforest near Cambodia\u2019s border with Thailand, lies at the heart of a region that has seen successive waves of resistance to malaria drugs arise in local people and then spread across the globe. As new waves of the disease threaten our health, worried scientists want to conduct a mass inoculation in a Cambodian region where new vaccines always seem to stop being effective.
Giving paracetamol (acetaminophen) to patients ill with severe malaria made them less likely to develop potentially fatal kidney failure. Each year severe malaria causes close to half a million deaths globally. Acute kidney injury occurs in 40% of adults and at least 10% of children with severe malaria, killing an estimated 40% of these adults and 12-24% of the children. The study reported for the first time that giving regular doses of paracetamol protects the kidney in adult patients with severe falciparum malaria.
FIEBRE aims to design new evidence-based guidelines to manage fever, thereby ensuring that patients get drugs that give them the best chance of recovery, and thereby help stop the spread of antimicrobial resistance (AMR), a major global health problem.
In collaboration with Cambodian authorities, MORU are running the Village Drama Against Malaria project for the third year. The project, which runs in 10 remote villages in March 2018, aims to create awareness about malaria prevention and early treatment.
Melioidosis is a bacterial infection that quietly causes thousands of deaths each year. Meet Direk Limmathurotsakul, the doctor who made it his mission to make the world take notice.
Myanmar-Oxford Clinical Research Unit (MOCRU) and partner Medical Action Myanmar (MAM) are performing a scrub typhus survey among fever patients attending the Puta-O clinic, a small, picturesque, secluded town surrounded by snow-capped Himalayan foothills in the far north of Myanmar over 1,500 km from Yangon.
To fight the growing global threat of antibiotic-resistant bacteria, food labels around the world should include an \u2018antibiotic footprint\u2019 section that clearly shows the type and amount of antibiotics used to produce that food, say scientists in a study led by Associate Professor Direk Limmathurotsakul.
Interested in science? Looking for a fun night out? Want to know what Pint of Science is all about? Come and join us for a one-night-only special, Casa Azul in Bangkok on the 1st February, where three world-class researchers will delve deep into the world of science.
Wellcome is announcing new collaborations with six institutions to find new ways to translate scientific discoveries into real world impact. The partnership with MORU will focus on closing the gap between research and implementing interventions, building capacity and expertise to support early translation to improve the health of people in low-income countries.
Professor Arjen Dondorp and colleagues are inching their way across the fringes of five Southeast Asian countries to test a triple combination therapy of antimalarial drugs. Results from the trial, being conducted in rural corners of Cambodia, Laos, Myanmar, Thailand and Vietnam, are due by mid-2018. This trial is also mentioned in the New York Times.
A collaboration between the University of Oxford and Thailand\u2019s Mahidol University has been shortlisted for the prestigious 2017 Newton Prize for its project aiming to understand the early stages of scrub typhus in Thailand.
Congratulations to Professor Sir Nick White, elected to the National Academy of Medicine (US). Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Work at the Cambodia Oxford Medical Research Unit (COMRU) and Angkor Hospital for Children (AHC) has highlighted the importance of melioidosis, infection by the soil-dwelling bacterium Burkholderia pseudomallei, as a cause of severe illness in Cambodian children.
The world\u2019s number-one treatment for malaria is on the brink of failure because of a new strain of drug-resistant parasites\u200a\u2014\u200aunless health policymakers take action. Professor Sir Nicholas White says that the mosquito-borne parasite responsible for severe malaria is now showing resistance to the prime treatment, Artemisinin Combination Therapy (ACT), across South-East Asia. If this resistance jumps to Africa, he warns, the tragedy will be on a massive scale.
MOCRU and its partner Medical Action Myanmar (MAM) have begun a study to identify areas in Myanmar where Burkholderia pseudomallei is present in the soil and where people are at risk of melioidosis, a difficult to diagnose deadly bacterial disease.
A highly drug resistant malaria \"superbug\" from western Cambodia is now present in southern Vietnam, leading to alarming failure rates for dihydroartemisinin (DHA)-piperaquine \u2014 Vietnam\u2019s national first-line malaria treatment, leading malaria scientists warn.
At their Annual Meeting 13 Sept, the Trustees of the Royal Society of Tropical Medicine and Hygiene (RSTMH) awarded MORU\u2019s Dr Direk Limmathurotsakul its Emerging Leaders Award.
The University of Oxford has conferred the title of Associate Professor to Yoel Lubell, Head of Economics and Translational Research at MORU, to Olivo Miotto from the Centre for Genomics and Global Health at MORU, and to Ronald Geskus from OUCRU. Louise Thwaites, Clinical Research Fellow at OUCRU, was appointed University Research Lecturer.
The WorldWide Antimalarial Resistance Network (WWARN) has been shortlisted for a 2017 Times Higher Education (THE) Award in the \u2018International Collaboration of the Year\u2019 category.
On 30 Aug 2017, Professor Lisa White, Head of Mathematical/Economic Modelling (MAEMOD) at MORU, led an engaging interactive Bangkok Scientifique session on the uses of mathematical modelling in infectious diseases at Caf\u00e9 Tartine in Bangkok.
In Southeast Asia, some types of the malaria parasite develop resistance to the drug combinations used to cure and prevent the disease. If this drug resistance spread to Africa, it\u2019d be a disaster. Fortunately, partners on the front lines are finding ways to fight back. Watch this video about the amazing work our team of SMRU researchers is doing to combat drug resistance in Thailand.
Changing home designs and materials to make homes cooler and harder for mosquitoes to enter could reduce malaria transmission in sub-Saharan Africa, according to a new study in The Lancet Planetary Health.
The first-ever MQPH Conference will take place at Keble College, Oxford on 23-28 September 2018. This international event will bring together people from public health, national regulatory authorities, pharmacy, biomedical, chemistry, law, ethics, cultural and social sciences, pharmaceutical industry, international organisations and NGOs. It grants an opportunity to discuss the problem and outline the necessary steps to tackle the issue on a global scale.
An existing malaria rapid diagnostic test (RDT) can be adapted to predict the delayed anaemia that can complicate severe malaria in patients treated with artemisinin-based antimalarial drugs
On 21 June 2017, the Cambodia Oxford Medical Research Unit (COMRU) and Angkor Hospital for Children (AHC) hosted the kick-off meeting for the multi-country Real-time Tracking of Neglected Bacterial Infectious Diseases Resistance Patterns Asia (TuNDRA) study.
![\"Traditional](\"https://www.tropmedres.ac/news/malaria2019s-ticking-time-bomb/responsive_image?ratio=r16x9&scale=w760\")
\n \n \n\n\n